

ASX Announcement

Melbourne, Australia, 31 March 2023

Exopharm Limited Despatch of Non-Renounceable Pro Rata Rights Issue Prospectus

Further to its announcement of 23 March 2023, genetic medicine and exosome-based drug-delivery company Exopharm Limited (ASX:EX1) is pleased to advise that the following documents in relation to its 1 for 1 non-renounceable pro rata entitlement offer (**Entitlement Offer**) have been despatched today to Eligible Shareholders, being Exopharm Limited shareholders as at 5:00 pm (AEDT) on 28 March 2023 with a registered address in Australia or New Zealand or who are shareholders that the Company has otherwise determined are eligible to participate:

- Non-renounceable pro rata rights issue prospectus (**Prospectus**); and
- personalised entitlement and acceptance form.

EX1 confirms that the Entitlement Offer contained in the Prospectus is now open and will close at 5:00 pm (AEST) on Thursday, 13 April 2023 unless extended (**Closing Date**). The Closing Date is the last date entitlement and acceptance forms and payment will be accepted by the Company (as stated in the indicative timetable included in the Prospectus).

By the Managing Director – this announcement has been authorised for release by the Managing Director.

[To discuss your entitlement, please contact your Adviser or the Joint Lead Managers below](#)

Craig Brown
Alto Capital
(08) 9223 9888
craig@altocapital.com.au
www.altocapital.com.au

Paul Hart
Canary Capital
0421 051 474
phart@canarycapital.com.au
www.canarycapital.com.au

Company and Media Enquiries:

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

www.exopharm.com

P: +61 (0)3 9111 0026

Ian Dixon
Managing Director

Tel: +61 418 561 907
ian.dixon@exopharm.com

ABOUT EXOPHARM

Exopharm (ASX:EX1) is a leader in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes.

Exosomes could be an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.